SCHEMBL24183451

SCHEMBL24183451

CS(=O)(=O)OCC1CCCN(C2CCN(C(=O)OCc3ccccc3)CC2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
CHRM1 P11229 2/20 0.49
CHRM2 P08172 1/20 0.49
CYP2C19 P33261 1/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
HTT P42858 1/20 0.47
PDE4B Q07343 1/20 0.45
ALDH1A1 P00352 1/20 0.45
GRIN2B Q13224 3/20 0.45
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29787242 1.00 SMN1; SMN2 (0.50) SMN1; SMN2NPC1RAB9ACHRM1CHRM2
SCHEMBL24183536 0.89 SMN1; SMN2 (0.55) SMN1; SMN2NPC1RAB9ACHRM1CHRM2
SCHEMBL30380328 0.89 SMN1; SMN2 (0.55) SMN1; SMN2NPC1RAB9ACHRM1CHRM2
SCHEMBL29787342 0.88 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ACHRM1CHRM2
SCHEMBL24183635 0.88 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ACHRM1CHRM2
SCHEMBL3444835 0.88 SMN1; SMN2 (0.50) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL4274599 0.88 SMN1; SMN2 (0.50) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL29787253 0.86 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ACHRM1CHRM2
SCHEMBL24183453 0.86 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9ACHRM1CHRM2
SCHEMBL29787295 0.86 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9ACHRM1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230115270-A1 INHIBITORS OF ADRENORECEPTOR ADRAC2 BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
WO-2022008426-A1 COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA BAYER AKTIENGESELLSCHAFT (DE) 2022-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230115270-A1 INHIBITORS OF ADRENORECEPTOR ADRAC2 ADRA2C, ADRB2, ADRB3 SMN1; SMN2 181/4885NPC1 707/4885RAB9A 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.